Jump to content

Scleroderma

From Wikipedia, the free encyclopedia
(Redirected from Sclerodermatomyositis)
This article is about the disease. For the mushroom, see Scleroderma (fungus).
Not to be confused with scleredema.

Scleroderma
A type of localized scleroderma known as morphea
SpecialtyRheumatology
Usual onsetMiddle age[1]
TypesLocalized, systemic scleroderma[2]
CausesUnknown[2]
Risk factorsFamily history, certain genetic factors, exposure to silica[3][4][5]
Diagnostic methodBased on symptoms, skin biopsy, blood tests[6]
Differential diagnosisMixed connective tissue disease, systemic lupus erythematosus, polymyositis, dermatomyositis[1]
TreatmentSupportive care[1]
MedicationCorticosteroids, methotrexate, non-steroidal anti-inflammatory drugs (NSAIDs)[2]
PrognosisLocalized: Normal life expectancy[7]
Systemic: Decreased life expectancy[3]
Frequency3 per 100,000 per year (systemic)[3]

Scleroderma is a group of autoimmune diseases that may result in changes to the skin, blood vessels, muscles, and internal organs.[2][6][8] The disease can be either localized to the skin or involve other organs, as well.[2] Symptoms may include areas of thickened skin, stiffness, feeling tired, and poor blood flow to the fingers or toes with cold exposure.[1] One form of the condition, known as CREST syndrome, classically results in calcium deposits, Raynaud's syndrome, esophageal problems, thickening of the skin of the fingers and toes, and areas of small, dilated blood vessels.[1]

The cause is unknown, but it may be due to an abnormal immune response.[2] Risk factors include family history, certain genetic factors, and exposure to silica.[3][4][5] The underlying mechanism involves the abnormal growth of connective tissue, which is believed to be the result of the immune system attacking healthy tissues.[6] Diagnosis is based on symptoms, supported by a skin biopsy or blood tests.[6]

While no cure is known, treatment may improve symptoms.[2] Medications used include corticosteroids, methotrexate, and non-steroidal anti-inflammatory drugs (NSAIDs).[2] Outcome depends on the extent of disease.[3] Those with localized disease generally have a normal life expectancy.[7] In those with systemic disease, life expectancy can be affected, and this varies based on subtype.[3] Death is often due to lung, gastrointestinal, or heart complications.[3]

About three per 100,000 people per year develop the systemic form.[3] The condition most often begins in middle age.[1] Women are more often affected than men.[1] Scleroderma symptoms were first described in 1753 by Carlo Curzio[9] and then well documented in 1842.[10] The term is from the Greek skleros meaning "hard" and derma meaning "skin".[11][12]

Signs and symptoms

[edit]
Arm of a person with scleroderma showing skin lesions
Dark, shiny skin on distal phalanges of both hands in systemic sclerosis

Potential signs and symptoms include:[13][14][15]

Cause

[edit]

Scleroderma is caused by genetic and environmental factors.[4][5][16][17] Mutations in HLA genes seem to play a crucial role in the pathogenesis of some cases; likewise silica, aromatic and chlorinated solvents, ketones, trichloroethylene, welding fumes, and white spirits exposure seems to contribute to the condition in a small proportion of affected persons.[4][5][16][17][18]

Pathophysiology

[edit]

Scleroderma is characterised by increased synthesis of collagen (leading to the sclerosis), damage to small blood vessels, activation of T lymphocytes, and production of altered connective tissue.[19] Its proposed pathogenesis is the following:[20][21][22][23][24]

  • It begins with an inciting event at the level of the vasculature, probably the endothelium. The inciting event is yet to be elucidated, but may be a viral agent, oxidative stress, or autoimmune. Endothelial cell damage and apoptosis ensue, leading to the vascular leakiness that manifests in early clinical stages as tissue oedema. At this stage, it is predominantly a Th1- and Th17-mediated disease.
  • After this, the vasculature is further compromised by impaired angiogenesis and impaired vasculogenesis (fewer endothelial progenitor cells), likely related to the presence of antiendothelinal cell antibodies (AECA). Despite this impaired angiogenesis, elevated levels of pro-angiogenic growth factors such as PDGF and VEGF is often seen in persons with the condition. The balance of vasodilation and vasoconstriction becomes askew, and the net result is vasoconstriction. The damaged endothelium then serves as a point of origin for blood-clot formation and further contributes to ischaemia-reperfusion injury and the generation of reactive oxygen species. These later stages are characterised by Th2 polarity.
  • The damaged endothelium upregulates adhesion molecules and chemokines to attract leucocytes, which enables the development of innate and adaptive immune responses, including loss of tolerance to various oxidised antigens, which includes topoisomerase I. B cells mature into plasma cells, which furthers the autoimmune component of the condition. T cells differentiate into subsets, including Th2 cells, which play a vital role in tissue fibrosis. Anti–topoisomerase 1 antibodies, in turn, stimulate type I interferon production.
  • Fibroblasts are recruited and activated by multiple cytokines and growth factors to generate myofibroblasts. Dysregulated transforming growth factor β (TGF-β) signalling in fibroblasts and myofibroblasts has been observed in multiple studies of scleroderma-affected individuals. Activation of fibroblasts and myofibroblasts leads to excessive deposition of collagen and other related proteins, leading to fibrosis. B cells are implicated in this stage, IL-6 and TGF-β produced by the B cells decrease collagen degradation and increase extracellular matrix production. Endothelin signalling is implicated in the pathophysiology of fibrosis.[25]

Vitamin D is implicated in the pathophysiology of the disease. An inverse correlation between plasma levels of vitamin D and scleroderma severity has been noted, and vitamin D is known to play a crucial role in regulating (usually suppressing) the actions of the immune system.[26]

Diagnosis

[edit]

Typical scleroderma is classically defined as symmetrical skin thickening, with about 70% of cases also presenting with Raynaud's phenomenon, nail-fold capillary changes, and antinuclear antibodies. Affected individuals may experience systemic organ involvement. No single test for scleroderma works all of the time, hence diagnosis is often a matter of exclusion. Atypical scleroderma may show any variation of these changes without skin changes or with finger swelling only.[27]

Laboratory testing can show antitopoisomerase antibodies, like anti-scl70 (causing a diffuse systemic form), or anticentromere antibodies (causing a limited systemic form and the CREST syndrome). Other autoantibodies can be seen, such as anti-U3 or anti-RNA polymerase.[28] Antidouble-stranded DNA autoantibodies are likely to be present in serum.[citation needed]

Differential

[edit]

Diseases that are often in the differential include:[29]

Classification

[edit]

Scleroderma is characterised by the appearance of circumscribed or diffuse, hard, smooth, ivory-colored areas that are immobile and which give the appearance of hidebound skin, a disease occurring in both localised and systemic forms:[30]

Treatment

[edit]

No cure for scleroderma is known, although relief of symptoms is often achieved; these include treatment of:[13][31]

Systemic disease-modifying treatment with immunosuppressants is often used.[16][32][33][34][35][36] Immunosuppressants used in its treatment include azathioprine, methotrexate, cyclophosphamide, mycophenolate, intravenous immunoglobulin, rituximab, sirolimus, alefacept, and the tyrosine kinase inhibitors, imatinib, nilotinib, and dasatinib.[16][31][32][33][34][35][36][37]

Experimental therapies under investigation include endothelin receptor antagonists, tyrosine kinase inhibitors, beta-glycan peptides, halofuginone, basiliximab, alemtuzumab, abatacept, and haematopoietic stem cell transplantation.[38][39]

Immunomodulatory agents in the treatment of scleroderma
INN Mechanism of action[40][41] Route of administration[40] Pregnancy category[40][42] Major toxicities[40]
Alefacept Monoclonal antibody to inhibit T lymphocyte activation by binding to CD2 portion of human leukocyte function antigen-3. IM B (US) Malignancies, injection site reactions, blood clots, lymphopenia, hepatotoxicity and infections.
Azathioprine Purine analogue that inhibits lymphocyte proliferation via conversion to mercaptopurine PO, IV D (Au) Myelosuppression and rarely malignancy, hepatitis, infection, hepatic sinusoidal obstruction syndrome and hypersensitivity reactions.
Cyclophosphamide Nitrogen mustard that cross-links DNA base pairs, leading to breakages and triggering apoptosis in haematopoietic cells. PO, IV D (Au) Vomiting, myelosuppression, haemorrhagic cystitis and rarely heart failure, pulmonary fibrosis, hepatic sinusoidal obstruction syndrome, malignancy and SIADH
Dasatinib Tyrosine kinase inhibitor against various proangiogenic growth factors (including PDGF and VEGF). PO D (Au) Fluid retention, myelosuppression, haemorrhage, infections, pulmonary hypertension, electrolyte anomalies and uncommonly hepatotoxicity, heart dysfunction/failure, myocardial infarction, QT interval prolongation, renal failure and hypersensitivity.
Imatinib As above PO D (Au) As above and rarely: GI perforation, avascular necrosis and rhabdomyolysis
Immunoglobulin Immunoglobulin, modulates the immune system. IV N/A Varies
Methotrexate Antifolate; inhibits dihydrofolate reductase. PO, IV, IM, SC, IT D (Au) Myeosuppression, pulmonary toxicity, hepatotoxicity, neurotoxicity and rarely kidney failure, hypersensitivity reactions, skin and bone necrosis, and osteoporosis
Mycophenolate Inosine monophosphate dehydrogenase inhibitor, leading to reduced purine biosynthesis in lymphocytes. PO, IV D (Au) Myelosuppression, blood clots, less commonly GI perforation/haemorrhage and rarely pancreatitis, hepatitis, aplastic anaemia and pure red cell aplasia.
Nilotinib As per dasatinib PO D (Au) As per imatinib
Rituximab Monoclonal antibody against CD20, which is expressed on B lymphocytes IV C (Au) Infusion-related reactions, infection, neutropenia, reduced immunoglobulin levels, arrhythmias, less commonly anaemia, thrombocytopenia, angina, myocardial infarction, heart failure, and rarely haemolytic anaemia, aplastic anaemia, serum sickness, severe skin conditions, pulmonary infiltrates, pneumonitis, cranial neuropathy (vision or hearing loss) and progressive multifocal leucoencephalopathy.
Sirolimus mTOR inhibitor, thereby reducing cytokine-induced lymphocyte proliferation. PO C (Au) Neutropenia, hypokalaemia, interstitial lung disease, pericardial effusion, pleural effusion, less commonly pulmonary haemorrhage, nephrotic syndrome, and rarely hepatotoxicity and lymphoedema.
PO = Oral. IV = Intravenous. IM = Intramuscular. SC = Subcutaneous. IT = Intrathecal.

The preferred pregnancy category, above, is Australian, if available. If unavailable, an American one is substituted.

Prognosis

[edit]

As of 2012, the five-year survival rate for systemic scleroderma was about 85%, whereas the 10-year survival rate was just under 70%.[43] This varies according to the subtype; while localized scleroderma rarely results in death, the systemic form can, and the diffuse systemic form carries a worse prognosis than the limited form. The major scleroderma-related causes of death are: pulmonary hypertension, pulmonary fibrosis, and scleroderma renal crisis.[28] People with scleroderma are also at a heightened risk for developing osteoporosis and for contracting cancer (especially liver, lung, haematologic, and bladder cancers).[44] Scleroderma is also associated with an increased risk of cardiovascular disease.[45]

According to a study of an Australian cohort, between 1985 and 2015, the average life expectancy of a person with scleroderma increased from 66 years to 74 years (the average Australian life expectancy increased from 76 to 82 years in the same period).[46]

Epidemiology

[edit]

Scleroderma most commonly first presents between the ages of 20 and 50 years, although any age group can be affected.[13][28] Women are four to nine times more likely to develop scleroderma than men.[28]

This disease is found worldwide.[28] In the United States, prevalence is estimated at 240 per million and the annual incidence of scleroderma is 19 per million people.[28] Likewise in the United States, it is slightly more common in African Americans than in their white counterparts. Choctaw Native Americans are more likely than Americans of European descent to develop the type of scleroderma that affects internal organs.[28] In Germany, the prevalence is between 10 and 150 per million people, and the annual incidence is between three and 28 per million people.[43] In South Australia, the annual incidence is 23 per million people, and the prevalence 233 per million people.[47]

Pregnancy

[edit]

Scleroderma in pregnancy is a complex situation; it increases the risk to both mother and child.[48] Overall, scleroderma is associated with reduced fetal weight for gestational age.[48] The treatment for scleroderma often includes known teratogens such as cyclophosphamide, methotrexate, mycophenolate, etc., so careful avoidance of such drugs during pregnancy is advised.[48] In these cases hydroxychloroquine and low-dose corticosteroids might be used for disease control.[48]

See also

[edit]

References

[edit]
  1. ^ a b c d e f g "Scleroderma". NORD (National Organization for Rare Disorders). 2007. Archived from the original on 8 September 2016. Retrieved 14 July 2017.
  2. ^ a b c d e f g h "Scleroderma". GARD. 2017. Archived from the original on 25 January 2017. Retrieved 14 July 2017.
  3. ^ a b c d e f g h Jameson L (2018). "Chapter 353". Harrison's Principles of Internal Medicine (20th ed.). McGraw Hill.
  4. ^ a b c d Barnes J, Mayes MD (March 2012). "Epidemiology of systemic sclerosis: incidence, prevalence, survival, risk factors, malignancy, and environmental triggers". Current Opinion in Rheumatology. 24 (2): 165–70. doi:10.1097/BOR.0b013e32834ff2e8. PMID 22269658. S2CID 24050211.
  5. ^ a b c d Greenblatt MB, Aliprantis AO (January 2013). "The immune pathogenesis of scleroderma: context is everything". Current Rheumatology Reports. 15 (1): 297. doi:10.1007/s11926-012-0297-8. PMC 3539168. PMID 23288576.
  6. ^ a b c d "Handout on Health: Scleroderma". NIAMS. August 2016. Archived from the original on 4 July 2017. Retrieved 15 July 2017.
  7. ^ a b Unsal E (2006). Current Opinions in Pediatric Rheumatology. Nova Publishers. p. 302. ISBN 9781594548710. Archived from the original on 2017-09-06.
  8. ^ Denton CP, Khanna D (October 2017). "Systemic sclerosis". Lancet. 390 (10103): 1685–1699. doi:10.1016/s0140-6736(17)30933-9. PMID 28413064. S2CID 22247432.
  9. ^ Mackay IR, Rose NR (2006). The Autoimmune Diseases. Academic Press. p. 369. ISBN 9780080454740.
  10. ^ Firestein GS, Kelley WN, Budd RC (2012). Kelley's Textbook of Rheumatology. Elsevier Health Sciences. p. 1366. ISBN 978-1437717389. Archived from the original on 2017-08-04.
  11. ^ Harper D. "scleroderma". Online Etymology Dictionary.
  12. ^ σκληρός, δέρμα. Liddell, Henry George; Scott, Robert; A Greek–English Lexicon at the Perseus Project.
  13. ^ a b c Hajj-ali, RA (June 2013). "Systemic Sclerosis". Merck Manual Professional. Merck Sharp & Dohme Corp. Archived from the original on 6 March 2014. Retrieved 5 March 2014.
  14. ^ Jimenez, SA, Cronin, PM, Koenig, AS, O'Brien, MS, Castro, SV (15 February 2012). Varga, J, Talavera, F, Goldberg, E, Mechaber, AJ, Diamond, HS (eds.). "Scleroderma Clinical Presentation". Medscape Reference. WebMD. Archived from the original on 6 March 2014. Retrieved 5 March 2014.
  15. ^ Longo D, Fauci A, Kasper D, Hauser S, Jameson J, Loscalzo J (2011). Harrison's Principles of Internal Medicine (18th ed.). New York: McGraw-Hill Professional. ISBN 978-0-07174889-6.[page needed]
  16. ^ a b c d Balbir-Gurman A, Braun-Moscovici Y (February 2012). "Scleroderma – new aspects in pathogenesis and treatment". Best Practice & Research. Clinical Rheumatology. 26 (1): 13–24. doi:10.1016/j.berh.2012.01.011. PMID 22424190.
  17. ^ a b Dospinescu P, Jones GT, Basu N (March 2013). "Environmental risk factors in systemic sclerosis". Current Opinion in Rheumatology. 25 (2): 179–83. doi:10.1097/BOR.0b013e32835cfc2d. PMID 23287382. S2CID 37543720.
  18. ^ Marie I, Gehanno JF, Bubenheim M, Duval-Modeste AB, Joly P, Dominique S, et al. (February 2014). "Prospective study to evaluate the association between systemic sclerosis and occupational exposure and review of the literature". Autoimmunity Reviews. 13 (2): 151–56. doi:10.1016/j.autrev.2013.10.002. PMID 24129037.
  19. ^ Valančienė G, Jasaitienė D, Valiukevičienė S (2010). "Pathogenesis and treatment modalities of localized scleroderma" (PDF). Medicina. 46 (10): 649–56. doi:10.3390/medicina46100092. PMID 21393982. Archived (PDF) from the original on 2014-03-06.
  20. ^ Katsumoto TR, Whitfield ML, Connolly MK (2011). "The pathogenesis of systemic sclerosis". Annual Review of Pathology. 6: 509–37. doi:10.1146/annurev-pathol-011110-130312. PMID 21090968.
  21. ^ Liakouli V, Cipriani P, Marrelli A, Alvaro S, Ruscitti P, Giacomelli R (August 2011). "Angiogenic cytokines and growth factors in systemic sclerosis". Autoimmunity Reviews. 10 (10): 590–94. doi:10.1016/j.autrev.2011.04.019. PMID 21549861.
  22. ^ Cipriani P, Marrelli A, Liakouli V, Di Benedetto P, Giacomelli R (August 2011). "Cellular players in angiogenesis during the course of systemic sclerosis". Autoimmunity Reviews. 10 (10): 641–46. doi:10.1016/j.autrev.2011.04.016. PMID 21549220.
  23. ^ Bosello S, De Luca G, Tolusso B, Lama G, Angelucci C, Sica G, et al. (August 2011). "B cells in systemic sclerosis: a possible target for therapy". Autoimmunity Reviews. 10 (10): 624–30. doi:10.1016/j.autrev.2011.04.013. PMID 21545850.
  24. ^ Hunzelmann N, Krieg T (May 2010). "Scleroderma: from pathophysiology to novel therapeutic approaches". Experimental Dermatology. 19 (5): 393–400. doi:10.1111/j.1600-0625.2010.01082.x. PMID 20507361. S2CID 40400573.
  25. ^ Leask A (June 2011). "The role of endothelin-1 signaling in the fibrosis observed in systemic sclerosis". Pharmacological Research. 63 (6): 502–03. doi:10.1016/j.phrs.2011.01.011. PMID 21315153.
  26. ^ Arnson Y, Amital H, Agmon-Levin N, Alon D, Sánchez-Castañón M, López-Hoyos M, et al. (June 2011). "Serum 25-OH vitamin D concentrations are linked with various clinical aspects in patients with systemic sclerosis: a retrospective cohort study and review of the literature". Autoimmunity Reviews. 10 (8): 490–94. doi:10.1016/j.autrev.2011.02.002. PMID 21320645.
  27. ^ Jimenez, SA, Cronin, PM, Koenig, AS, O'Brien, MS, Castro, SV (15 February 2012). Varga, J, Talavera, F, Goldberg, E, Mechaber, AJ, Diamond, HS (eds.). "Scleroderma Workup". Medscape Reference. WebMD. Archived from the original on 6 March 2014. Retrieved 6 March 2014.
  28. ^ a b c d e f g Jimenez, SA, Cronin, PM, Koenig, AS, O'Brien, MS, Castro, SV (15 February 2012). Varga, J, Talavera, F, Goldberg, E, Mechaber, AJ, Diamond, HS (eds.). "Scleroderma". Medscape Reference. WebMD. Archived from the original on 6 March 2014. Retrieved 5 March 2014.
  29. ^ Jimenez, SA, Cronin, PM, Koenig, AS, O'Brien, MS, Castro, SV (15 February 2012). Varga, J, Talavera, F, Goldberg, E, Mechaber, AJ, Diamond, HS (eds.). "Scleroderma Differential Diagnoses". Medscape Reference. WebMD. Archived from the original on 6 March 2014. Retrieved 6 March 2014.
  30. ^ Elston W, James WD, Berger TG, Dirk M (2006). Andrew's diseases of the skin: clinical dermatology (10 ed.). Philadelphia, PA: Saunders Elsevier. pp. 169–172. ISBN 978-0808923510.
  31. ^ a b Walker KM, Pope J (August 2012). "Treatment of systemic sclerosis complications: what to use when first-line treatment fails--a consensus of systemic sclerosis experts". Seminars in Arthritis and Rheumatism. 42 (1): 42–55. doi:10.1016/j.semarthrit.2012.01.003. PMID 22464314.
  32. ^ a b Fett N (July–August 2013). "Scleroderma: nomenclature, etiology, pathogenesis, prognosis, and treatments: facts and controversies". Clinics in Dermatology. 31 (4): 432–37. doi:10.1016/j.clindermatol.2013.01.010. PMID 23806160.
  33. ^ a b Shah AA, Wigley FM (April 2013). "My approach to the treatment of scleroderma". Mayo Clinic Proceedings. 88 (4): 377–93. doi:10.1016/j.mayocp.2013.01.018. PMC 3666163. PMID 23541012.
  34. ^ a b Kowal-Bielecka O, Bielecki M, Kowal K (2013). "Recent advances in the diagnosis and treatment of systemic sclerosis" (PDF). Polskie Archiwum Medycyny Wewnetrznej. 123 (1–2): 51–58. PMID 23344666. Archived (PDF) from the original on 2014-03-06.
  35. ^ a b Beyer C, Dees C, Distler JH (January 2013). "Morphogen pathways as molecular targets for the treatment of fibrosis in systemic sclerosis". Archives of Dermatological Research. 305 (1): 1–8. doi:10.1007/s00403-012-1304-7. PMID 23208311. S2CID 25073736.
  36. ^ a b Leask A (June 2012). "Emerging targets for the treatment of scleroderma". Expert Opinion on Emerging Drugs. 17 (2): 173–79. doi:10.1517/14728214.2012.678833. PMID 22533795. S2CID 29026417.
  37. ^ Manno R, Boin F (November 2010). "Immunotherapy of systemic sclerosis". Immunotherapy. 2 (6): 863–78. doi:10.2217/imt.10.69. PMC 3059511. PMID 21091117.
  38. ^ Postlethwaite AE, Harris LJ, Raza SH, Kodura S, Akhigbe T (April 2010). "Pharmacotherapy of systemic sclerosis". Expert Opinion on Pharmacotherapy. 11 (5): 789–806. doi:10.1517/14656561003592177. PMC 2837533. PMID 20210685.
  39. ^ Ong VH, Denton CP (May 2010). "Innovative therapies for systemic sclerosis". Current Opinion in Rheumatology. 22 (3): 264–72. doi:10.1097/BOR.0b013e328337c3d6. PMID 20190640. S2CID 24631979.
  40. ^ a b c d Rossi, S, ed. (2013). Australian Medicines Handbook (2013 ed.). Adelaide: The Australian Medicines Handbook Unit Trust. ISBN 978-0-9805790-9-3.[page needed]
  41. ^ Brunton, L, Chabner, B, Knollman, B (2010). Goodman and Gilman's The Pharmacological Basis of Therapeutics (12th ed.). New York: McGraw-Hill Professional. ISBN 978-0-07-162442-8.[page needed]
  42. ^ "Medscape Multispecialty – Home page". WebMD. Archived from the original on 13 November 2013. Retrieved 27 November 2013.[full citation needed]
  43. ^ a b Sticherling M (October 2012). "Systemic sclerosis-dermatological aspects. Part 1: Pathogenesis, epidemiology, clinical findings". Journal der Deutschen Dermatologischen Gesellschaft. 10 (10): 705–18, quiz 716. doi:10.1111/j.1610-0387.2012.07999.x. PMID 22913330. S2CID 7422759.
  44. ^ Calderon LM, Domsic RT, Shah AA, Pope JE (May 2023). "Preventative Care in Scleroderma: What Is the Best Approach to Bone Health and Cancer Screening?". Rheumatic Disease Clinics of North America. 49 (2): 411–423. doi:10.1016/j.rdc.2023.01.011. PMC 10845237. PMID 37028844.
  45. ^ Cen X, Feng S, Wei S, Yan L, Sun L (November 2020). "Systemic sclerosis and risk of cardiovascular disease: A PRISMA-compliant systemic review and meta-analysis of cohort studies". Medicine. 99 (47): e23009. doi:10.1097/MD.0000000000023009. PMC 7676589. PMID 33217802.
  46. ^ Kennedy N, Walker J, Hakendorf P, Roberts-Thomson P (23 March 2018). "Improving life expectancy of patients with scleroderma: results from the South Australian Scleroderma Register". Internal Medicine Journal. 48 (8): 951–56. doi:10.1111/imj.13799. PMID 29573101. S2CID 4230441.
  47. ^ Nikpour M, Stevens WM, Herrick AL, Proudman SM (December 2010). "Epidemiology of systemic sclerosis". Best Practice & Research. Clinical Rheumatology. 24 (6): 857–69. doi:10.1016/j.berh.2010.10.007. PMID 21665131.
  48. ^ a b c d Lidar M, Langevitz P (May 2012). "Pregnancy issues in scleroderma". Autoimmunity Reviews. 11 (6–7): A515–19. doi:10.1016/j.autrev.2011.11.021. PMID 22155199.
[edit]
Retrieved from "https://wiki.riteme.site/w/index.php?title=Scleroderma&oldid=1242962707"